Price T Rowe Associates Inc. MD Buys Shares of 700,334 CryoPort Inc (NASDAQ:CYRX)
Price T Rowe Associates Inc. MD bought a new stake in shares of CryoPort Inc (NASDAQ:CYRX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 700,334 shares of the consumer goods maker’s stock, valued at approximately $12,830,000.
Other large investors have also recently added to or reduced their stakes in the company. Axiom International Investors LLC DE acquired a new stake in CryoPort during the 2nd quarter valued at approximately $1,810,000. SG Americas Securities LLC acquired a new stake in CryoPort during the 2nd quarter valued at approximately $249,000. Marshall Wace North America L.P. acquired a new stake in CryoPort during the 2nd quarter valued at approximately $941,000. AWM Investment Company Inc. acquired a new stake in CryoPort during the 2nd quarter valued at approximately $641,000. Finally, Handelsbanken Fonder AB acquired a new stake in CryoPort during the 2nd quarter valued at approximately $2,933,000. 59.59% of the stock is owned by institutional investors and hedge funds.
A number of research firms have weighed in on CYRX. Needham & Company LLC began coverage on shares of CryoPort in a research report on Monday, July 1st. They set a “buy” rating and a $22.00 target price for the company. Svb Leerink reissued an “outperform” rating on shares of CryoPort in a research report on Monday, July 15th. ValuEngine downgraded shares of CryoPort from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. B. Riley set a $26.00 target price on shares of CryoPort and gave the company a “buy” rating in a research report on Friday, July 19th. Finally, BidaskClub cut CryoPort from a “sell” rating to a “strong sell” rating in a report on Saturday. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $24.00.
CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Thursday, August 8th. The consumer goods maker reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $8.46 million for the quarter, compared to analysts’ expectations of $7.94 million. CryoPort had a negative return on equity of 17.32% and a negative net margin of 35.71%. The company’s revenue for the quarter was up 82.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.09) EPS. On average, equities research analysts forecast that CryoPort Inc will post -0.3 EPS for the current year.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Further Reading: Discount Rate
Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort Inc (NASDAQ:CYRX).
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.